Texas Neurology. P.A.

Dallas, Texas 75214

2 studies enrolling now · 44 studies all time

What they study most

ALS, Agitation in Participants With Dementia of the Alzheimer's Type, Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Central Nervous System Diseases, Cervical Dystonia, Early Alzheimer's Disease, Epilepsies, Partial, Epilepsy

Studies at this site

• Study of COYA 302 for the Treatment of ALS — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease — Recruiting now
• Safety Study of Oral Edaravone Administered in Subjects With ALS — Completed
• Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) — Completed
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease — Running, not enrolling
• A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications — Running, not enrolling
• A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease — Running, not enrolling
• A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) — Completed
• Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type — Stopped early
• A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache — Completed
• Open Label Extension Study of AMX0035 in Patients With ALS — Completed
• Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease — Completed
• Open-label Extension for Phase 3 Clinical Trials of Simufilam — Stopped early
• A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) — Stopped early
• A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) — Stopped early
• AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) — Completed
• Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) — Stopped early
• Multiple Doses of AT-1501-A201 in Adults With ALS — Completed
• Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1) — Completed
• Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type — Completed
• Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS) — Completed
• A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease — Completed
• A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) — Completed
• Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS) — Stopped early
• A Study for Patients Who Completed VITALITY-ALS (CY 4031) — Completed
• Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures — Completed
• Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo — Completed
• Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS) — Stopped early
• A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) — Stopped early
• Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo — Stopped early
• An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine — Completed
• Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis — Withdrawn before enrolling
• Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine — Completed
• ESCAPE Migraine Trial — Stopped early
• Eslicarbazepine Acetate Monotherapy Long Term Study — Completed
• Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab — Stopped early
• Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients — Stopped early
• Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs — Completed
• Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients — Stopped early
• A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients — Stopped early
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed
• Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis — Completed